MétaCan
Menu
Back to cohort
Record W4414149792 · doi:10.1016/j.ejphar.2025.178132

Dual acting inhibitor of soluble epoxide hydrolase and Cyclooxygenase-2, attenuates glomerular injury in renal hypoplasia mice

2025· article· en· W4414149792 on OpenAlexfundno aff
Abdul H. Khan, Samaneh Goorani, Anna Atamanchuk, Wojciech K. Jankiewicz, Michael M. Yeboah, Scott D. Barnett, John R. Falck, Sung Hee Hwang, Bodgan Barnych, Bruce D. Hammock, Ashraf El‐Meanawy, John D. Imig

Bibliographic record

VenueEuropean Journal of Pharmacology · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicEicosanoids and Hypertension Pharmacology
Canadian institutionsnot available
FundersNational Center for Advancing Translational SciencesNational Institute of Environmental Health SciencesNational Institute of Mental HealthNational Institutes of HealthJuvenile Diabetes Research Foundation CanadaNational Institute of Diabetes and Digestive and Kidney DiseasesArkansas Research AllianceArkansas Biosciences InstituteWelch Foundation
KeywordsAlbuminuriaFocal segmental glomerulosclerosisKidneyPodocyteEpoxide hydrolase 2GlomerulosclerosisGlomerulonephritisRenal glomerulus

Abstract

fetched live from OpenAlex

Glomerular diseases like focal and segmental glomerulosclerosis (FSGS) are the leading cause of chronic and end-stage kidney diseases. Although FSGS is associated with high morbidity and mortality, available treatments are limited, which emphasizes the need for novel therapy. We developed a dual inhibitor, PTUPB, that concurrently acts as a soluble epoxide hydrolase (sEH) inhibitor and a cyclooxygenase-2 (COX-2) inhibitor. In the current study, we investigated renal actions of PTUPB in a genetic renal hypoplasia FSGS model, ROP Os/+ mice. ROP Os/+ mice developed albuminuria and glomerular injury between 16 and 20 weeks of age with an 8-fold higher albumin/Cr ratio than wild-type ROP +/+ mice. Three groups were assessed: 20-week-old ROP +/+ mice, ROP Os/+ mice treated with vehicle, and ROP Os/+ mice treated with PTUPB (10 mg/kg/d, i.p.). After 4 weeks, urine, blood, and kidney tissue were collected in the mice groups for biochemical, molecular, and histological analysis. ROP Os/+ mice had 10-fold higher albuminuria than ROP +/+ mice, and PTUPB treatment markedly attenuated albuminuria in ROP Os/+ mice by 69 %. ROP Os/+ mice developed a glomerular injury with a 3-fold higher glomerular injury score and 10-fold higher glomerular expression of sclerotic marker fibronectin than ROP +/+ mice, and PTUPB treatment attenuated these by 40-50 %. We further demonstrated that there was significantly lower renal mRNA expression of nephrin, podocin, podoplanin, synaptopodin, and glomerular WT1 immunopositive cells in ROP Os/+ mice which was improved by PTUPB treatment in these mice. Glomerular permeability studies in isolated glomeruli determined that COX-2 metabolites of 8,9-epoxyeicosatrienoic acid (EET) increased glomerular permeability. PTUPB, 8,9-EET, or 8,9-EET analogs prevented angiotensin II-induced glomerular permeability and mesangial cell proliferation. These findings demonstrate that COX-2 metabolites harm the glomerulus, whereas 8,9-EET improves glomerular function. Lastly, kidney fibrosis and inflammation were increased in ROP Os/+ mice compared to ROP +/+ mice. PTUPB treatment to ROP Os/+ mice decreased kidney fibrosis and inflammation. These findings demonstrate that the dual inhibitor PTUPB that concurrently inhibits sEH and COX-2 is a potential treatment for FSGS and related glomerular diseases.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.271
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractno

Explore more

Same venueEuropean Journal of PharmacologySame topicEicosanoids and Hypertension PharmacologyFrench-language works237,207